<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p137" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_137{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_137{left:796px;bottom:1195px;letter-spacing:0.13px;}
#t3_137{left:130px;bottom:1115px;letter-spacing:-0.01px;}
#t4_137{left:277.4px;bottom:1115.2px;letter-spacing:-0.22px;}
#t5_137{left:183.3px;bottom:1099px;letter-spacing:-0.21px;}
#t6_137{left:418px;bottom:1099px;letter-spacing:-0.01px;}
#t7_137{left:130px;bottom:1083px;letter-spacing:-0.01px;}
#t8_137{left:282.2px;bottom:1082.8px;letter-spacing:-0.22px;}
#t9_137{left:183.3px;bottom:1066.5px;letter-spacing:-0.21px;}
#ta_137{left:289px;bottom:1066px;letter-spacing:-0.01px;}
#tb_137{left:130px;bottom:1050px;letter-spacing:-0.01px;}
#tc_137{left:282.2px;bottom:1050.3px;letter-spacing:-0.22px;}
#td_137{left:183.3px;bottom:1034.1px;letter-spacing:-0.21px;}
#te_137{left:739px;bottom:1034px;}
#tf_137{left:185px;bottom:1018px;letter-spacing:-0.01px;}
#tg_137{left:130px;bottom:1002px;letter-spacing:-0.01px;}
#th_137{left:554.3px;bottom:1001.6px;letter-spacing:-0.21px;}
#ti_137{left:183.3px;bottom:985.4px;letter-spacing:-0.21px;}
#tj_137{left:681px;bottom:985px;letter-spacing:-0.01px;}
#tk_137{left:185px;bottom:969px;letter-spacing:-0.01px;}
#tl_137{left:130px;bottom:953px;letter-spacing:-0.01px;}
#tm_137{left:259.1px;bottom:953px;letter-spacing:-0.21px;}
#tn_137{left:183.3px;bottom:936.7px;letter-spacing:-0.21px;}
#to_137{left:308px;bottom:937px;letter-spacing:-0.01px;}
#tp_137{left:130px;bottom:921px;letter-spacing:-0.01px;}
#tq_137{left:261.3px;bottom:920.5px;letter-spacing:-0.21px;}
#tr_137{left:183.3px;bottom:904.3px;letter-spacing:-0.21px;}
#ts_137{left:183.3px;bottom:888.1px;letter-spacing:-0.21px;}
#tt_137{left:530px;bottom:888px;letter-spacing:-0.01px;}
#tu_137{left:185px;bottom:872px;letter-spacing:-0.01px;}
#tv_137{left:130px;bottom:856px;letter-spacing:-0.01px;}
#tw_137{left:261.3px;bottom:855.6px;letter-spacing:-0.21px;}
#tx_137{left:183.3px;bottom:839.5px;letter-spacing:-0.21px;}
#ty_137{left:183.3px;bottom:823.3px;letter-spacing:-0.2px;}
#tz_137{left:183.3px;bottom:807px;letter-spacing:-0.21px;}
#t10_137{left:709px;bottom:807px;letter-spacing:-0.01px;}
#t11_137{left:185px;bottom:791px;letter-spacing:-0.01px;}
#t12_137{left:130px;bottom:775px;letter-spacing:-0.01px;}
#t13_137{left:258.4px;bottom:774.6px;letter-spacing:-0.22px;}
#t14_137{left:183.3px;bottom:758.4px;letter-spacing:-0.22px;}
#t15_137{left:183.3px;bottom:742.1px;letter-spacing:-0.21px;}
#t16_137{left:340px;bottom:742px;letter-spacing:-0.01px;}
#t17_137{left:130px;bottom:726px;letter-spacing:-0.01px;}
#t18_137{left:271.3px;bottom:725.9px;letter-spacing:-0.21px;}
#t19_137{left:183.3px;bottom:709.7px;letter-spacing:-0.21px;}
#t1a_137{left:183.3px;bottom:693.5px;letter-spacing:-0.19px;}
#t1b_137{left:235px;bottom:693px;letter-spacing:-0.01px;}
#t1c_137{left:130px;bottom:677px;letter-spacing:-0.01px;}
#t1d_137{left:265.6px;bottom:677.2px;letter-spacing:-0.22px;}
#t1e_137{left:183.3px;bottom:661px;letter-spacing:-0.22px;}
#t1f_137{left:183.3px;bottom:644.8px;letter-spacing:-0.21px;}
#t1g_137{left:500px;bottom:645px;letter-spacing:-0.01px;}
#t1h_137{left:130px;bottom:612px;letter-spacing:-0.01px;}
#t1i_137{left:267.6px;bottom:612.4px;letter-spacing:-0.22px;}
#t1j_137{left:183.3px;bottom:596.2px;letter-spacing:-0.21px;}
#t1k_137{left:587px;bottom:596px;letter-spacing:-0.01px;}
#t1l_137{left:185px;bottom:580px;letter-spacing:-0.01px;}
#t1m_137{left:130px;bottom:564px;letter-spacing:-0.01px;}
#t1n_137{left:263px;bottom:563.7px;letter-spacing:-0.21px;}
#t1o_137{left:183.3px;bottom:547.5px;letter-spacing:-0.21px;}
#t1p_137{left:689px;bottom:547px;letter-spacing:-0.01px;}
#t1q_137{left:185px;bottom:531px;letter-spacing:-0.01px;}
#t1r_137{left:130px;bottom:515px;letter-spacing:-0.01px;}
#t1s_137{left:246.8px;bottom:515px;letter-spacing:-0.21px;}
#t1t_137{left:183.3px;bottom:498.9px;letter-spacing:-0.2px;}
#t1u_137{left:183.3px;bottom:482.6px;letter-spacing:-0.22px;}
#t1v_137{left:536px;bottom:483px;letter-spacing:-0.01px;}
#t1w_137{left:185px;bottom:466px;letter-spacing:-0.01px;}
#t1x_137{left:130px;bottom:450px;letter-spacing:-0.01px;}
#t1y_137{left:256.1px;bottom:450.2px;letter-spacing:-0.21px;}
#t1z_137{left:183.3px;bottom:434px;letter-spacing:-0.21px;}
#t20_137{left:588px;bottom:434px;letter-spacing:-0.01px;}
#t21_137{left:185px;bottom:418px;letter-spacing:-0.01px;}
#t22_137{left:130px;bottom:402px;letter-spacing:0.09px;}
#t23_137{left:250.8px;bottom:401.9px;letter-spacing:-0.11px;}
#t24_137{left:761px;bottom:402px;letter-spacing:0.09px;}
#t25_137{left:185px;bottom:386px;letter-spacing:0.1px;}
#t26_137{left:130px;bottom:369px;letter-spacing:-0.01px;}
#t27_137{left:389.1px;bottom:369.1px;letter-spacing:-0.21px;}
#t28_137{left:183.3px;bottom:352.9px;letter-spacing:-0.21px;}
#t29_137{left:630px;bottom:353px;letter-spacing:-0.01px;}
#t2a_137{left:185px;bottom:337px;letter-spacing:-0.01px;}
#t2b_137{left:130px;bottom:321px;letter-spacing:-0.01px;}
#t2c_137{left:315px;bottom:320.5px;letter-spacing:-0.22px;}
#t2d_137{left:755px;bottom:321px;}
#t2e_137{left:185px;bottom:304px;letter-spacing:-0.01px;}
#t2f_137{left:130px;bottom:288px;letter-spacing:-0.01px;}
#t2g_137{left:259.3px;bottom:288px;letter-spacing:-0.21px;}
#t2h_137{left:183.3px;bottom:271.8px;letter-spacing:-0.22px;}
#t2i_137{left:425px;bottom:272px;letter-spacing:-0.01px;}
#t2j_137{left:130px;bottom:256px;letter-spacing:-0.01px;}
#t2k_137{left:273.7px;bottom:255.5px;letter-spacing:-0.21px;}
#t2l_137{left:183.3px;bottom:239.3px;letter-spacing:-0.22px;}
#t2m_137{left:185px;bottom:223px;letter-spacing:-0.01px;}
#t2n_137{left:130px;bottom:207px;letter-spacing:-0.01px;}
#t2o_137{left:265.6px;bottom:206.8px;letter-spacing:-0.21px;}
#t2p_137{left:183.3px;bottom:190.6px;letter-spacing:-0.22px;}
#t2q_137{left:183.3px;bottom:174.4px;letter-spacing:-0.22px;}
#t2r_137{left:301px;bottom:174px;letter-spacing:-0.01px;}
#t2s_137{left:130px;bottom:158px;letter-spacing:-0.01px;}
#t2t_137{left:270.7px;bottom:158.2px;letter-spacing:-0.21px;}
#t2u_137{left:183.3px;bottom:142px;letter-spacing:-0.21px;}
#t2v_137{left:613px;bottom:142px;letter-spacing:-0.01px;}
#t2w_137{left:185px;bottom:126px;letter-spacing:-0.01px;}
#t2x_137{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_137{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_137{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_137{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_137{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
.t.m0_137{transform:matrix(0.957,0,-0.29,0.96,0,0);}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts137" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg137Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg137" style="-webkit-user-select: none;"><object width="908" height="1286" data="137/137.svg" type="image/svg+xml" id="pdf137" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_137" class="t s0_137">13. Bibliography </span><span id="t2_137" class="t s1_137">137 </span>
<span id="t3_137" class="t s2_137">186. Blanchard, P., et al.,</span><span id="t4_137" class="t m0_137 s3_137">Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a </span>
<span id="t5_137" class="t m0_137 s3_137">comprehensive analysis by tumor site.</span><span id="t6_137" class="t s2_137">Radiother Oncol, 2011.100(1): pp. 33-40. </span>
<span id="t7_137" class="t s2_137">187. Forastiere, AA, et al.,</span><span id="t8_137" class="t m0_137 s3_137">Concurrent chemotherapy and radiotherapy for organ preservation in advanced </span>
<span id="t9_137" class="t m0_137 s3_137">laryngeal cancer.</span><span id="ta_137" class="t s2_137">J Chem, 2003.349(22): p. 2091-8. </span>
<span id="tb_137" class="t s2_137">188. Forastiere, AA, et al.,</span><span id="tc_137" class="t m0_137 s3_137">Long-term results of RTOG 91-11: a comparison of three nonsurgical </span>
<span id="td_137" class="t m0_137 s3_137">Treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.</span><span id="te_137" class="t s2_137">J Clin </span>
<span id="tf_137" class="t s2_137">Oncol, 2013.31(7): pp. 845-52. </span>
<span id="tg_137" class="t s2_137">189. Department of Veterans Affairs Laryngeal Cancer Study, G., et al.,</span><span id="th_137" class="t m0_137 s3_137">Induction chemotherapy plus radiation </span>
<span id="ti_137" class="t m0_137 s3_137">compared with surgery plus radiation in patients with advanced laryngeal cancer.</span><span id="tj_137" class="t s2_137">J Chem, 1991.324(24): </span>
<span id="tk_137" class="t s2_137">pp. 1685-90. </span>
<span id="tl_137" class="t s2_137">190. Strojan, P., et al.,</span><span id="tm_137" class="t m0_137 s3_137">Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: </span>
<span id="tn_137" class="t m0_137 s3_137">A systematic review.</span><span id="to_137" class="t s2_137">Head Neck, 2016.38 Supplement 1:p.E2151-8. </span>
<span id="tp_137" class="t s2_137">191. Budach, V., et al.,</span><span id="tq_137" class="t m0_137 s3_137">Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5- </span>
<span id="tr_137" class="t m0_137 s3_137">FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long- </span>
<span id="ts_137" class="t m0_137 s3_137">term results of the ARO 95-06 randomized phase III trial.</span><span id="tt_137" class="t s2_137">Int J Radiat Oncol Biol Phys, 2015.91(5): pp. </span>
<span id="tu_137" class="t s2_137">916-24. </span>
<span id="tv_137" class="t s2_137">192. Budach, V., et al.,</span><span id="tw_137" class="t m0_137 s3_137">Hyperfractionated accelerated chemoradiation with concurrent fluorouracilmitomycin is </span>
<span id="tx_137" class="t m0_137 s3_137">more effective than dose-escalated hyperfractionated accelerated radiation </span>
<span id="ty_137" class="t m0_137 s3_137">therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative </span>
<span id="tz_137" class="t m0_137 s3_137">clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.</span><span id="t10_137" class="t s2_137">J Clin Oncol, </span>
<span id="t11_137" class="t s2_137">2005.23(6): pp. 1125-35. </span>
<span id="t12_137" class="t s2_137">193. Bourhis, J., et al.,</span><span id="t13_137" class="t m0_137 s3_137">Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without </span>
<span id="t14_137" class="t m0_137 s3_137">concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label </span>
<span id="t15_137" class="t m0_137 s3_137">phase 3 randomized trial.</span><span id="t16_137" class="t s2_137">Lancet Oncology, 2012.13(2): pp. 145-53. </span>
<span id="t17_137" class="t s2_137">194. Bonner, J. A., et al.,</span><span id="t18_137" class="t m0_137 s3_137">Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year </span>
<span id="t19_137" class="t m0_137 s3_137">survival data from a phase 3 randomized trial, and relationship between cetuximabinduced rash and </span>
<span id="t1a_137" class="t m0_137 s3_137">survival.</span><span id="t1b_137" class="t s2_137">Lancet Oncology, 2010.11(1): pp. 21-8. </span>
<span id="t1c_137" class="t s2_137">195. Budach, W., et al.,</span><span id="t1d_137" class="t m0_137 s3_137">Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent </span>
<span id="t1e_137" class="t m0_137 s3_137">radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and </span>
<span id="t1f_137" class="t m0_137 s3_137">neck (HNSCC): A meta-analysis of randomized trials.</span><span id="t1g_137" class="t s2_137">Radiother Oncol, 2016.118(2): pp. 238-43. </span>
<span id="t1h_137" class="t s2_137">196. Lefebvre, JL, et al.,</span><span id="t1i_137" class="t m0_137 s3_137">Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy </span>
<span id="t1j_137" class="t m0_137 s3_137">for larynx preservation: the TREMPLIN randomized phase II study.</span><span id="t1k_137" class="t s2_137">J Clin Oncol, 2013.31(7): pp. </span>
<span id="t1l_137" class="t s2_137">853-9. </span>
<span id="t1m_137" class="t s2_137">197. Janoray, G., et al.,</span><span id="t1n_137" class="t m0_137 s3_137">Long-term Results of a Multicenter Randomized Phase III Trial of Induction </span>
<span id="t1o_137" class="t m0_137 s3_137">Chemotherapy With Cisplatin, 5-fluorouracil, +/- Docetaxel for Larynx Preservation.</span><span id="t1p_137" class="t s2_137">J Natl Cancer Inst, </span>
<span id="t1q_137" class="t s2_137">2016.108(4). </span>
<span id="t1r_137" class="t s2_137">198. Dietz, A., et al.,</span><span id="t1s_137" class="t m0_137 s3_137">Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy </span>
<span id="t1t_137" class="t m0_137 s3_137">(IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in </span>
<span id="t1u_137" class="t m0_137 s3_137">resectable laryngeal and hypopharyngeal cancer (LHSCC).</span><span id="t1v_137" class="t s2_137">Journal of Clinical Oncology, 2016.34( </span>
<span id="t1w_137" class="t s2_137">15_suppl): p. 6025-6025. </span>
<span id="t1x_137" class="t s2_137">199. Bonner, J., et al.,</span><span id="t1y_137" class="t m0_137 s3_137">Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and </span>
<span id="t1z_137" class="t m0_137 s3_137">Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.</span><span id="t20_137" class="t s2_137">JAMA Otolaryngol Head Neck </span>
<span id="t21_137" class="t s2_137">Surg, 2016.142(9): p. 842-9. </span>
<span id="t22_137" class="t s1_137">200. Bourhis, J., et al.,</span><span id="t23_137" class="t m0_137 s2_137">Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.</span><span id="t24_137" class="t s1_137">Journal </span>
<span id="t25_137" class="t s1_137">of Clinical Oncology, 2006.368(9538): pp. 843-54. </span>
<span id="t26_137" class="t s2_137">201. Winquist, E., C. Cripps, and C. Agbassi,</span><span id="t27_137" class="t m0_137 s3_137">Epidermal growth factor receptor (EGFR) targeted therapy in stage III </span>
<span id="t28_137" class="t m0_137 s3_137">and IV head and neck cancer. Evidence-Based Series No. 5-12, version 2.1</span><span id="t29_137" class="t s2_137">. 2011, Toronto: Cancer Care </span>
<span id="t2a_137" class="t s2_137">Ontario (CCO). </span>
<span id="t2b_137" class="t s2_137">202. Seiwert, TY and EE Cohen,</span><span id="t2c_137" class="t m0_137 s3_137">State-of-the-art management of locally advanced head and neck cancer.</span><span id="t2d_137" class="t s2_137">Br J </span>
<span id="t2e_137" class="t s2_137">Cancer, 2005.92(8): p. 1341-8. </span>
<span id="t2f_137" class="t s2_137">203. Brizel, DM, et al.,</span><span id="t2g_137" class="t m0_137 s3_137">Hyperfractionated irradiation with or without concurrent chemotherapy for </span>
<span id="t2h_137" class="t m0_137 s3_137">locally advanced head and neck cancer.</span><span id="t2i_137" class="t s2_137">J Chem, 1998.338(25): pp. 1798-804. </span>
<span id="t2j_137" class="t s2_137">204. Adelstein, DJ, et al.,</span><span id="t2k_137" class="t m0_137 s3_137">An intergroup phase III comparison of standard radiation therapy and two schedules </span>
<span id="t2l_137" class="t m0_137 s3_137">of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. </span>
<span id="t2m_137" class="t s2_137">J Clin Oncol, 2003.21(1): pp. 92-8. </span>
<span id="t2n_137" class="t s2_137">205. Budach, W., et al.,</span><span id="t2o_137" class="t m0_137 s3_137">A meta-analysis of hyperfractionated and accelerated radiotherapy and combined </span>
<span id="t2p_137" class="t m0_137 s3_137">chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of </span>
<span id="t2q_137" class="t m0_137 s3_137">the head and neck.</span><span id="t2r_137" class="t s2_137">BMC Cancer, 2006.6:p. 28. </span>
<span id="t2s_137" class="t s2_137">206. Nutting, CM, et al.,</span><span id="t2t_137" class="t m0_137 s3_137">Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck </span>
<span id="t2u_137" class="t m0_137 s3_137">cancer (PARSPORT): a phase 3 multicentre randomized controlled trial.</span><span id="t2v_137" class="t s2_137">Lancet Oncology, 2011.12(2): pp. </span>
<span id="t2w_137" class="t s2_137">127-36. </span>
<span id="t2x_137" class="t s0_137">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
